Literature DB >> 18982744

Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.

Josip Grah1, Mirko Samija, Antonio Juretić, Bozena Sarcević, Hrvoje Sobat.   

Abstract

The aim of this study was to explore the expression of cancer/testis tumor associated antigens (C/T TAAs) MAGE-A 3/4 and NY-ESO-1 in lung squamous cell carcinoma and adenocarcinoma, and to evaluate their association with the standard clinical-pathological features of surgically treated lung cancer patients. The study included 80 patients with non-small cell lung cancer (40 adenocarcinomas, 40 squamous cell carcinomas) who had undergone surgery in the period between 2002 and 2005. The MAGE-A3/4 and NY-ESO-1 antigen expression was analyzed immunohistochemically (IHC). The results showed MAGE-A3/4 and NY-ESO-1 positive staining in 65.1% and 23.3% of squamous cell carcinomas and 18.9% and 10.8% of adenocarcinomas, respectively. A statistically higher MAGE-A3/4 expression was observed in planocellular bronchial carcinoma (p < 0.001), while no difference was found in the expression of NY-ESO-1 in adenocarcinoma and planocellular carcinoma (p = 0.144). A significant association was found between the MAGE-A3/4 expression and presence of tumor necrosis in squamous cell cancer specimens (p = 0.001), but not in adenocarcinoma (p = 0.033). A statistically significant association was noted between the NY-ESO-1 expression and positive hilar and mediastinal lymph nodes in adenocarcinoma (p = 0.025) whereas it was not the case in squamous cell carcinoma. Non-small cell lung cancer frequently expresses cancer/testis tumor associated antigens. Our results demonstrate that the MAGE-A3/4 and NY-ESO-1 expression was significant associated with prognostic factors of poor outcome of disease (presence of tumor necrosis and lymph node metastasis). As C/T antigens are important for inducing a specific immune reaction in lung cancer patients, there is an intention to form a subgroup of patients in the future, whose treatment would be enhanced by specific immunotherapy based on the observed scientific results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18982744

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  7 in total

1.  Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.

Authors:  Chunxia Su; Ying Xu; Xuefei Li; Shengxiang Ren; Chao Zhao; Likun Hou; Zhiwei Ye; Caicun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  [Lung cancer. Molecular pathology and personalized therapy].

Authors:  A Schultheis; J Wolf; R Büttner
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

3.  Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.

Authors:  Sang Hyun Kim; Sangyull Lee; Chang Hun Lee; Min Ki Lee; Young Dae Kim; Dong Hoon Shin; Kyung Un Choi; Jee Yeon Kim; Do Youn Park; Mee Young Sol
Journal:  Lung       Date:  2009-10-01       Impact factor: 2.584

4.  Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.

Authors:  Xinfeng Chen; Liping Wang; Jinyan Liu; Lan Huang; Li Yang; Qun Gao; Xiaojuan Shi; Jieyao Li; Feng Li; Zhen Zhang; Song Zhao; Bin Zhang; Pierre Van der Bruggen; Yi Zhang
Journal:  Oncol Lett       Date:  2017-02-01       Impact factor: 2.967

5.  Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression.

Authors:  Zhenbo Hou; Xiao Liang; Xinmei Wang; Ziqiang Zhou; Guilan Shi
Journal:  Oncol Lett       Date:  2020-03-31       Impact factor: 2.967

Review 6.  Actual status of therapeutic vaccination in non-small cell lung cancer.

Authors:  Katarzyna Szyszka-Barth; Katarzyna Ramlau; Joanna Goździk-Spychalska; Lukasz Spychalski; Maciej Bryl; Iwona Gołda-Gocka; Anna Kopczyńska; Aleksander Barinow-Wojewódzki; Rodryg Ramlau
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03

Review 7.  [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].

Authors:  Frances A Shepherd; Jean-Yves Douillard; George R Blumenschein
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.